Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Oramed Pharmaceuticals Inc. ORMP

Healthcare  —  Biotechnology
4.73 (0.06) (1.25%) as of 25 Sep
Market cap
$199.3M
P/E
1.1×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Oramed Pharmaceuticals Inc. (ORMP) Business Profile

Updated before January 2025

Company Overview

Oramed Pharmaceuticals Inc. (ORMP) is a clinical-stage pharmaceutical company that specializes in the development of innovative oral drug delivery systems. Founded in 2006 and headquartered in New York, USA, Oramed aims to revolutionize the way medications are administered by transitioning injectable treatments to oral formulations. The company was co-founded by Nadav Kidron, who currently serves as the Chief Executive Officer (CEO). Under his leadership, Oramed has grown into a pioneering force in the pharmaceutical industry, leveraging its proprietary Protein Oral Delivery (POD™) technology to address unmet medical needs.

Oramed’s leadership team includes experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and business development. The company’s scientific advisory board comprises leading experts in endocrinology and drug delivery systems, further strengthening its position as a leader in oral drug innovation.

Core Business Segments

Oral Insulin (ORMD-0801)

One of Oramed’s flagship products is ORMD-0801, an oral insulin capsule designed to provide a non-invasive alternative to injectable insulin for diabetes patients. This product is currently in advanced clinical trials and has the potential to transform diabetes management by improving patient compliance and quality of life.

Oral GLP-1 Analog (ORMD-0901)

Another key product in Oramed’s pipeline is ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) analog. This drug is being developed for the treatment of type 2 diabetes and obesity. GLP-1 analogs are typically administered via injection, but Oramed’s oral formulation could significantly expand the market for these therapies.

Licensing and Partnerships

Oramed also generates revenue through licensing agreements and partnerships. The company collaborates with pharmaceutical firms to commercialize its proprietary POD™ technology for various therapeutic applications. These partnerships allow Oramed to diversify its revenue streams and expand its global footprint.

Business Model

Oramed’s business model is centered around innovation, licensing, and strategic partnerships. The company invests heavily in research and development (R&D) to advance its proprietary POD™ technology and bring new oral drug formulations to market. Revenue is primarily generated through licensing agreements, milestone payments, and royalties from commercialized products.

By focusing on oral drug delivery, Oramed addresses a significant market need for non-invasive treatment options. This approach not only enhances patient compliance but also reduces healthcare costs associated with injectable therapies. The company’s emphasis on collaboration with global pharmaceutical firms further strengthens its market position and accelerates the commercialization of its products.

Strategic Direction

Oramed is committed to advancing its clinical pipeline and expanding its portfolio of oral drug formulations. The company’s strategic priorities include:

  • Advancing Clinical Trials: Oramed is focused on completing late-stage clinical trials for ORMD-0801 and ORMD-0901, with the goal of obtaining regulatory approval and launching these products in key markets.
  • Expanding Partnerships: The company aims to establish new licensing agreements and collaborations to leverage its POD™ technology for additional therapeutic areas.
  • Sustainability Goals: Oramed is exploring ways to minimize its environmental impact by adopting sustainable practices in its R&D and manufacturing processes.
  • Geographic Expansion: Oramed plans to enter emerging markets where the demand for innovative diabetes treatments is growing rapidly.

Competitive Landscape

Oramed operates in a highly competitive pharmaceutical industry, where it faces competition from both established players and emerging biotech firms. Key competitors include:

  • Novo Nordisk: A global leader in diabetes care, Novo Nordisk offers a range of injectable insulin and GLP-1 analogs.
  • Eli Lilly: Another major player in the diabetes market, Eli Lilly develops innovative therapies for diabetes management, including injectable and oral formulations.
  • Biocon: An Indian biopharmaceutical company that specializes in biosimilars and diabetes treatments.
  • Rani Therapeutics: A biotech firm focused on developing oral biologics using its proprietary RaniPill™ technology.

Despite the competition, Oramed’s unique POD™ technology and focus on oral drug delivery provide a significant competitive advantage.

Risk Factors

Oramed faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The approval process for new drugs is complex and time-consuming, posing a significant risk to Oramed’s product pipeline.
  • Market Dependence: The company’s reliance on a limited number of products increases its vulnerability to market fluctuations and competitive pressures.
  • Supply Chain Disruptions: Any disruptions in the supply chain could delay clinical trials and product launches.
  • Intellectual Property Risks: Protecting its proprietary technology is critical for Oramed’s success, and any infringement could harm its competitive position.

Recent Developments

In recent years, Oramed has achieved several milestones:

  • Clinical Trial Progress: The company has made significant advancements in its Phase 3 clinical trials for ORMD-0801, bringing it closer to regulatory approval.
  • Partnerships: Oramed entered into a licensing agreement with Hefei Tianhui Incubator of Technologies Co., Ltd. (HTIT) for the commercialization of ORMD-0801 in China.
  • Innovation: The company continues to invest in R&D to enhance its POD™ technology and explore new therapeutic applications.
  • Global Developments: The COVID-19 pandemic highlighted the importance of non-invasive drug delivery systems, increasing interest in Oramed’s oral formulations.

Investment Considerations

Strengths

  • Innovative Technology: Oramed’s POD™ technology offers a unique solution to the challenges of oral drug delivery.
  • Strong Pipeline: The company’s focus on diabetes treatments addresses a large and growing market.
  • Strategic Partnerships: Collaborations with global pharmaceutical firms enhance Oramed’s market reach and revenue potential.

Risks

  • Regulatory Uncertainty: The lengthy approval process for new drugs poses a risk to Oramed’s timeline.
  • Market Competition: The company faces intense competition from established players in the diabetes market.
  • Financial Risks: As a clinical-stage company, Oramed relies on external funding to support its operations.

Conclusion

Oramed Pharmaceuticals Inc. is at the forefront of innovation in oral drug delivery, with a strong focus on addressing unmet medical needs in diabetes care. The company’s proprietary POD™ technology and robust clinical pipeline position it as a leader in the pharmaceutical industry. While challenges such as regulatory hurdles and market competition remain, Oramed’s strategic direction and commitment to innovation provide a solid foundation for future growth. Investors seeking exposure to the biotech sector may find Oramed an attractive opportunity, given its potential to disrupt traditional drug delivery methods and capture significant market share.